BAY-Y 3118 |
| Catalog No.GC32356 |
BAY-Y 3118은 항균 활성이 있는 새로운 클로로플루오로퀴놀론입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 151213-16-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
BAY-Y 3118 is a new chlorofluoroquinolone with antimicrobial activity.
BAY-Y 3118 is potent against Haemophilhs influenzae, Moraxela catarrhalis, Acinetobacter baumannii, Xanthomonas maltophiia, gram-positive cocci, and anaerobes; MICs for 50%o of the strains (MIC50s) and MIC90s are ≤0.015 and ≤0.015, ≤0.015 and ≤0.015, 0.03 and 2, 0.25 and 0.5, 0.06 and 1, and 0.12 and 0.25 μg/mL, respectively[1]. The cellular concentration-to-extracellular concentration ratio of BAY-Y 3118 is higher than 6.3 at extracellular concentrations ranging from 2 to 100 mg/L. The uptake of BAY-Y 3118 is rapid, reversible and nonsaturable. The intracellular penetration of BAY-Y 3118 is significantly affected by environmental temperature and cell viability. BAY-Y 3118 reaches high intracellular concentrations within human polymorphonuclear leukocytes (PMNs) and remains active intracellularly[2]. All strains of L. monocytogenes and other Listeria spp. are highly susceptible; the MICs for these organisms ranges from 0.062 to 0.25 μg/mL. BAY-Y 3118 is rapidly bactericidal in vitro, with a postantibiotic effect occurring for 3 h after removal of the antibiotic. L. monocytogenes is eliminated from infected L929 cells treated with BAY-Y 3118, suggesting a bactericidal effect on the listeriae in these cells[3].
Immunocompetent mice are rapidly cured by treatment with 4 mg every 12 h. Concomitantly, the levels of interleukin 6 and gamma interferon in mouse sera decline rapidly. In immunocompetent mice, treatment with 2 mg of BAY-Y 3118 every 12 h results in a greater initial reduction in the listerial counts in the organs than treatment with 2 mg of ampicillin every 12 h. BAY-Y 3118 completely eliminates L. monocytogenes from the livers and spleens of chronically infected nude mice[3].
[1]. Fass RJ, et al. In vitro activity of Bay y 3118, a new quinolone. Antimicrob Agents Chemother. 1993 Nov;37(11):2348-57. [2]. García I, et al. Intracellular penetration and activity of BAY Y 3118 in human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1994 Oct;38(10):2426-9. [3]. Nichterlein T, et al. Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells. Antimicrob Agents Chemother. 1994 Jul;38(7):1501-6.
Cell experiment: | Agar plates are prepared and used within 1 day after preparation. The inhibition of bacterial growth is also assessed in tissue culture medium (RPMI 1640 with L-glutamine and 10% fetal calf serum. In brief, 10000 cells of L. monocytogenes EGD are incubated for 8 h in the presence of the antibiotic. Thereafter, the number of bacteria is determined by plating in tryptose agar. The lowest concentration of the antibiotic that inhibited growth in this system is considered the minimal effective concentration in tissue culture medium[3]. |
Animal experiment: | Mice: Mice are treated intraperitoneally every 12 h with BAY-Y 3118 (1, 2, or 4 mg per animal in 0.2 mL of PBS starting 6 h postinfection). Control animals receive 0.2 mL of PBS only. At days 1, 3, and 6 postinfection, five mice from each group are killed by cervical dislocation and their spleens and livers are removed aseptically. The organs are homogenized in isotonic saline with Tenbroeck tissue grinders and are further diluted in isotonic saline. The bacterial counts per organ are determined by plating of appropriate dilutions of the homogenates in tryptose agar by a pour plate technique[3]. |
References: [1]. Fass RJ, et al. In vitro activity of Bay y 3118, a new quinolone. Antimicrob Agents Chemother. 1993 Nov;37(11):2348-57. | |
| Cas No. | 151213-16-0 | SDF | |
| Canonical SMILES | O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N(C4)C[C@]5([H])[C@@]4([H])CCCN5)=C3Cl)C1=O)O | ||
| Formula | C20H21ClFN3O3 | M.Wt | 405.85 |
| Solubility | DMSO : 33.33 mg/mL (82.12 mM; ultrasonic and warming and heat to 60°C) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.464 mL | 12.3198 mL | 24.6396 mL |
| 5 mM | 492.8 μL | 2.464 mL | 4.9279 mL |
| 10 mM | 246.4 μL | 1.232 mL | 2.464 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *